Figure 1: Patient single-cell CAR-T product PSI associated significantly with clinical outcome (Rossi 2017).
Figure 2: CD4+ CAR-T example showing non-redundant cytokines contributing to PSI differences (Rossi 2017).
Figure 3: IsoPlexis’ superior tracking used single-cell polyfunctional strength to monitor melanoma patients and predict relapse (Ma 2013).
Rossi J, Paczkowski P, Shen Y, Morse K, Flynn B, Kaiser A, Ng C, Gallatin K, Cain T, Fan R, Mackay S, Heath JR, Rosenberg SA, Kochenderfer JN, Zhou J, and Bot A. Polyfunctional Anti-CD19 CAR T Cells Determined by Single-Cell Multiplex Proteomics Associated with Clinical Activity in Patients with Advanced Non-Hodgkin’s Lymphoma. Presented at AACR 2017, Session MS.CL10.01 - Clinical Biomarkers.
Lu Y, Xue Q, Eisele MR, Sulistijo E, Brower K, Han L, Amir ED, Pe’er D, Miller-Jensen K, and Fan R. Highly Multiplexed Profiling of Immune Effector Functions Reveals Deep Functional Heterogeneity in Response to Pathogenic Ligands. Proc. Natl. Acad. Sci., 112 (7), 607-615 (2015).
Ma C, Cheung AF, Chodon T, Koya RC, Wu Z, Ng C, Avramis E, Cochran AJ, Witte ON, Baltimore D, Chmielowski B, Economou JS, Comin-Anduix B, Ribas A, and Heath JR. Multifunctional T Cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy. Cancer Discovery, 3, 418 (2013).
Lu Y, Chen JJ, Mu L, Xue Q, Wu Y, Wu PH, Li J, Vortmeyer AO, Miller-Jensen K, Wirtz D, and Fan R. High-throughput Secretomic Analysis of Single Cells to Assess Functional Cellular Heterogeneity. Analytical Chemistry, 85 (4), 2548– 2556 (2013).
Ma C, Fan R, Ahmad H, Shi Q, Comin-Anduix B, Chodon T, Koya RC, Liu CC, Kwong GA, Radu CG, Ribas A, and Heath JR. A Clinical Microchip for Evaluation of Single Immune Cells Reveals High Functional Heterogeneity in Phenotypically Similar T Cells. Nature Medicine, 17, 738-743 (2011).
CAR T Cell Functionality Found to Correlate With Outcomes for Patients With NHL. "Through this research, we were able to highlight the important role a functionally versatile subpopulation of CAR T cells may play in the fight against cancer, leading to new ways to characterize and optimize T-cell products," Adrian Bot, MD, Kite’s vice president, Translational Medicine, said in a statement. "These insights were made possible by using the IsoPlexis technology."
IsoPlexis Research, in Collaboration with Oncology Specialist Kite Pharma, Offers Hope for Targeted CAR-T Treatment. US-based biotech firm IsoPlexis has presented findings from research using the company’s precision engineering platform, called IsoCode. The data show the potential to predict whether cancer patients will respond to CAR-T cell therapy prior to treatment, as well as to improve both pre-infusion potency testing and cell product design.
CAR T Cell Functionality Correlates With Outcomes, Offering a Biomarker for Response. The flexibility of CAR T cells to perform multiple functions was associated with the level of clinical activity elicited for patients with advanced non-Hodgkin’s lymphoma (NHL). For the biomarker assessment, PSI was determined by an analysis of pre-infusion CAR T cells using a single-cell, high-multiplexing ELISA system developed by IsoPlexis.
IsoPlexis and Kite Pharma Report Clinical Biomarker Data at AACR. IsoPlexis collaboration offers breakthrough insights into detecting and predicting patient response to t-cell therapy. Data captured by IsoCode, IsoPlexis' single-cell precision engineering platform, detected a statistically significant association between the potency of CAR-T cell product prior to treatment and objective response of cancer patients post-treatment. The results highlight the potential to predict whether cancer patients will respond to CAR-T cell therapy prior to treatment, as well as to improve both pre-infusion potency testing and cell product design.
IsoPlexis Awarded NIH SBIR Grant to Develop Single-Cell Analysis Platform to Facilitate Cancer Immunotherapy. IsoPlexis was recently awarded a competitive Phase I Small Business Innovation Research (SBIR) grant from the National Cancer Institute of the National Institutes of Health to develop a multi-protein, single-cell analysis platform to facilitate personalized cancer immunotherapy response detection.
Local Dream Team Develops Cancer Treatment That's Saving Lives. A dream team of Caltech and UCLA scientists and doctors have created a treatment that's giving hope to cancer patients who once had none. The medication was developed by chemistry professor James Heath and his lab at Caltech in Pasadena, who work day and night, to help UCLA oncologist Antoni Ribas try to cure his incurable cancer patients.
Immune-Cell Therapy could Strengthen Promising Melanoma Treatment. A new study of genetically modified immune cells by scientists from UCLA and the California Institute of Technology could help improve a promising treatment for melanoma, an often fatal form of skin cancer.
Get the Picture for Personalized Medicine: Microchip Platform Can Create Movie of the Immune System During the Course of Treatment. Dr. James Heath and his colleagues at the California Institute of Technology have developed an enabling microfluidic technology called the Single Cell Barcode Chip (SCBC). The SCBC is currently being used in a melanoma clinical trial where researchers are engineering patients’ immune systems to attack their own cancer.
Improving Health Assessments with a Single Cell. Research led by scientists from the California Institute of Technology (Caltech) has shown that a new generation of microchips developed by the team can quickly and inexpensively assess immune function by examining biomarkers—proteins that can reflect the response of the immune system to disease—from single cells.